Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |